Agios Pharmaceuticals, Inc. (AGIO)

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know

Agios' Growth Story Hinges on Mitapivat's Commercial Expansion

Bank of New York Mellon Corp Invests $7.37 Million in Agios Pharmaceuticals, Inc. $AGIO

Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Recommendation of “Hold” by Brokerages

AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year

Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript

Agios Pharmaceuticals Q2 Earnings Call Highlights

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release